CNS Drugs

, Volume 9, Issue 4, pp 271–280 | Cite as

Mixed Anxiety and Depression

Diagnosis and Treatment Options
Disease Management

Summary

Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depression can be enormous, affecting both the individual and society.

The clinician must be creative when treating patients with mixed anxiety and depressive symptoms; psychopharmacological treatment can involve the use of a variety of mono- and polytherapies. Benzodiazepines can be effective in treating anxiety symptoms, but unwanted adverse effects limit their use to the short term. Tricyclic antidepressants, although proven to be effective in treating both anxiety and depressive symptoms, have numerous adverse effects, making them a second-choice therapy. Traditional monoamine oxidase inhibitors have proven efficacy in atypical depression, and the newer reversible and selective inhibitors of monoamine oxidase-A may prove to be very effective in treating both sets of symptoms. Of particular importance in the treatment of patients with anxiety and depressive symptoms are the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors, nefazodone and the azapirones (including buspirone).

Keywords

Depressive Symptom Adis International Limited Social Phobia Panic Disorder Clin Psychiatry 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Robins LN, Locke BZ, Regier DA. An overview of psychiatric disorders in America. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the Epidemiologic Catchment Area Study. New York: Free Press, 1991: 328–66Google Scholar
  2. 2.
    Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996; 168Suppl. 30: 17–30Google Scholar
  3. 3.
    Angst J, Merikangas KR, Scheidegger P, et al. Recurrent brief depression: a new subtype of affective disorder. J Affect Disord 1990; 19: 87–98PubMedCrossRefGoogle Scholar
  4. 4.
    Angst J, Vollrath M, Merikangas KR, et al. Comorbidity of anxiety and depression in the Zurich Cohort Study of young adults. In: Maser JD, Cloninger CR, editors. Comorbidity of mood and anxiety disorders. Washington, DC: American Psychiatric Press, 1990: 123–37Google Scholar
  5. 5.
    Ball SG, Buchwald AM, Waddell MT, et al. Depression and generalized anxiety symptoms in panic disorder: implications for comorbidity. J Nerv Ment Dis 1995; 183: 304–8PubMedCrossRefGoogle Scholar
  6. 6.
    Blazer D, Schwartz M, Woodbury M, et al. Depressive symptoms and depressive diagnoses in a community population: use of a new procedure for analysis of psychiatric comorbidity. Arch Gen Psychiatry 1988; 45: 1078–84PubMedCrossRefGoogle Scholar
  7. 7.
    Breslau N, Davis GC. DSM-III generalized anxiety disorder: an empirical investigation of more stringent criteria. Psychiatr Res 1985; 14: 231–8CrossRefGoogle Scholar
  8. 8.
    Breslau N, Davis GC. Further evidence on the doubtful validity of generalized anxiety disorder [letter]. Psychiatr Res 1985; 16: 177–9CrossRefGoogle Scholar
  9. 9.
    Cassano GB, Michelini S. Pharmacological treatment of depression and comorbid anxiety disorders. Adv Biochem Psychopharmacol 1995; 49: 113–25PubMedGoogle Scholar
  10. 10.
    Katon W, Roy-Byrne PP. Mixed anxiety and depression. J Abnorm Psychol 1991; 100: 337–45PubMedCrossRefGoogle Scholar
  11. 11.
    Barrett JE, Barrett JA, Oxman TE, et al. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 1988; 45: 1100–6PubMedCrossRefGoogle Scholar
  12. 12.
    Liebowitz MR. Treating the patient with depression and associated anxiety. In: Serotonin —Reshaping the Treatment of Depression. MEDICINE Publishing Foundation Symposium Series, 32. Toronto: The Medicine Group (Canada) Ltd., 1992: 31–41Google Scholar
  13. 13.
    Boulenger J-P, Lavallée Y-J. Mixed anxiety and depression: diagnostic issues. J Clin Psychiatry 1993; 54Suppl. 1: 3–8PubMedGoogle Scholar
  14. 14.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987Google Scholar
  15. 15.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  16. 16.
    Hamilton M. Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry 1989; 154: 201–6PubMedCrossRefGoogle Scholar
  17. 17.
    Fava GA, Grandi S, Zielezny M, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994; 151: 1295–9PubMedGoogle Scholar
  18. 18.
    Stahl SM. Mixed anxiety and depression: clinical implications. J Clin Psychiatry 1993; 54Suppl. 1: 33–8PubMedGoogle Scholar
  19. 19.
    World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and guidelines. Geneva: WHO, 1992Google Scholar
  20. 20.
    Wittchen HU, Essau CA. Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence? J Clin Psychiatry 1993; 54Suppl. 1: 9–15PubMedGoogle Scholar
  21. 21.
    Thase ME, Simons AD, McGreary J, et al. Relapse after cognitive behavioral therapy of depression: potential implications for longer course of treatment. Am J Psychiatry 1992; 149: 1046–52PubMedGoogle Scholar
  22. 22.
    Keller MB, Hanks DL. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995; 56Suppl. 6: 22–9PubMedGoogle Scholar
  23. 23.
    Zajecka JM, Ross JS. Management of comorbid anxiety and depression. J Clin Psychiatry 1995; 56 Suppl. 2: 10–3Google Scholar
  24. 24.
    Kahn RJ, McMair DM, Lipman RS, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Arch Gen Psychiatry 1986; 43: 79–85PubMedCrossRefGoogle Scholar
  25. 25.
    Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988; 49: 293–301PubMedGoogle Scholar
  26. 26.
    Johnstone EC, Cunningham Owens DG, Frith CD, et al. Neurotic illness and its response to anxiolytic and antidepressant treatment. Psychological Med 1980; 10: 321–8CrossRefGoogle Scholar
  27. 27.
    Rickels K, Cdanalosi I, Chung HR, et al. Amitriptyline in anxious-depressed outpatients: a controlled study. Am J Psychiatry 1974; 131(1): 25–30PubMedGoogle Scholar
  28. 28.
    Rickels K, Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry 1993; 54 Suppl.: 20–3PubMedGoogle Scholar
  29. 29.
    Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988; 45: 129–37PubMedCrossRefGoogle Scholar
  30. 30.
    Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988; 145: 306–11PubMedGoogle Scholar
  31. 31.
    Versiani M, Mundim FD, Nardi AE, et al. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988; 8: 279–83PubMedCrossRefGoogle Scholar
  32. 32.
    Liebowitz MR, Quitkin FM, Stewart JW, et al. Effect of panic attacks on the treatment of atypical depressives. Psychopharmacol Bull 1985; 21(3): 558–61PubMedGoogle Scholar
  33. 33.
    Lydiard RB. Co-existing depression and anxiety: special diagnostic and treatment issues. J Clin Psychiatry 1991; 52Suppl. 6: 48–54PubMedGoogle Scholar
  34. 34.
    Angst J, Stabl M. Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology 1992; 106 Suppl.: 109–3CrossRefGoogle Scholar
  35. 35.
    Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992; 43(4): 561–96PubMedCrossRefGoogle Scholar
  36. 36.
    Bakish D, Saxena BM, Bowen R, et al. Reversible monoamine oxidase A inhibitors in panic disorder. Clin Neuropharmacology 1993; 16(2 Suppl.): 77S–82SGoogle Scholar
  37. 37.
    Johnson MR, Lydiard RB, Ballenger JC. MAOIs in panic disorder and agoraphobia. In: Kennedy SH, editor. Clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press, Inc., 1994: 205–24Google Scholar
  38. 38.
    Versiani M, Nardi AE, Mundim FD, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353–60PubMedCrossRefGoogle Scholar
  39. 39.
    Bakish D. The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia. J Clin Psychopharmacol 1994; 14(1): 74–5PubMedCrossRefGoogle Scholar
  40. 40.
    Wakelin J. Differential effects of fluvoxamine, imipramine and placebo on anxiety in depression [abstract]. 16th Congress Collequium Internationale Neuropsycho-pharmacologicum: 1988; MunichGoogle Scholar
  41. 41.
    Dunbar GC, Fuell DL. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 1992; 6Suppl. 4: 81–90PubMedCrossRefGoogle Scholar
  42. 42.
    den Boer JA, Westenberg GM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59–74CrossRefGoogle Scholar
  43. 43.
    Roy-Byrne P, Wingerson D, Cowley D, et al. Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr Clin North Am 1993; 16(4): 719–35PubMedGoogle Scholar
  44. 44.
    Montgomery S, McIntrye M, Osterheide R, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993; 3(2): 143–52PubMedCrossRefGoogle Scholar
  45. 45.
    McDougle CJ, Goodman WK, Leckman JF, et al. The psychopharmacology of obsessive compulsive disorder: implications for treatment and pathogenesis. Psychiatr Clin North Am 1993; 16(4): 749–66PubMedGoogle Scholar
  46. 46.
    Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54: 435–8PubMedGoogle Scholar
  47. 47.
    Sternbach H. Fluoxetine treatment of social phobia. J Clin Psychopharmacol 1990; 10(3): 230–1PubMedCrossRefGoogle Scholar
  48. 48.
    DeWilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87: 141–5CrossRefGoogle Scholar
  49. 49.
    Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand 1990; 81: 185–9PubMedCrossRefGoogle Scholar
  50. 50.
    Houck C, Stankovic S. An open-label study of fluvoxamine in outpatients with mixed anxiety-depressive disorder [poster no. 118]. 37th Annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) program: 1997 May 27–30; Boca RatonGoogle Scholar
  51. 51.
    Carrasco JL, Diaz-Marsa M, Saiz J. Sertraline in the treatment of mixed anxiety and depression disorder [in Spanish]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25(3): 141–5PubMedGoogle Scholar
  52. 52.
    Boyer WF, Feighner JP. Side effects of the selective serotonin re-uptake inhibitors. In: Feighner JP, Boyer WF, editors. Selective serotonin re-uptake inhibitors. Chichester: John Wiley & Sons, 1991: 109–17Google Scholar
  53. 53.
    Bakish D, Hooper CL, Filteau M-J, et al. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996; 32(1): 135–41PubMedGoogle Scholar
  54. 54.
    Schneier F, Campeas R, Fallon B, et al. Buspirone in social phobia [abstract no. O-12-7-8]. Presented at the 17th Congress of Collegium Internationale Neuro-Psychpharmacologium: 1991 Sep 10–14, KyotoGoogle Scholar
  55. 55.
    Schwiezer EE, Amsterdam J, Rickels K, et al. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 1986; 22: 183–5Google Scholar
  56. 56.
    Fabre LF. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 1990; 51Suppl. 9: 55–61PubMedGoogle Scholar
  57. 57.
    Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 1996; 57: 287–91PubMedGoogle Scholar
  58. 58.
    Sussman N. How to manage anxious patients who are depressed. J Clin Psychiatry 1993; 54(5 Suppl.): 8–16PubMedGoogle Scholar
  59. 59.
    Rickels K, Robinson DS, Schweizer E, et al. Nefazodone: aspects of efficacy. J Clin Psychiatry 1995; 56Suppl. 6: 43–6PubMedGoogle Scholar
  60. 60.
    Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57Suppl. 2: 31–8PubMedGoogle Scholar
  61. 61.
    Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995; 56Suppl. 6: 37–42PubMedGoogle Scholar
  62. 62.
    Zajecka JM. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996; 57: 10–5PubMedGoogle Scholar
  63. 63.
    DeMartinis NA, Schweizer E, Rickels K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996; 57: 245–8PubMedGoogle Scholar
  64. 64.
    Stewart JW, Quitkin FM, McGrath PJ. Nefazodone may relieve anxiety within two weeks in anxious-depressives [poster 119]. 37th Annual meeting of the New Clinical Drug Evaluation Unit (NCDEU) program: 1997 May 27–30; Boca RatonGoogle Scholar
  65. 65.
    Lydiard RB, Laraia MT, Ballenger JC, et al. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 1987; 144: 664–5PubMedGoogle Scholar
  66. 66.
    Marks J. The benzodiazepines. Lancaster: MTP Press Limited, 1985: 100–5Google Scholar
  67. 67.
    Lecrubier Y, Bourin M, Moon CAL, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997; 95: 485–93PubMedCrossRefGoogle Scholar
  68. 68.
    Khan A, Upton V, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 1998; 18: 19–25PubMedCrossRefGoogle Scholar
  69. 69.
    Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998; 47: 55–62PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • David Bakish
    • 1
    • 2
    • 3
  • Rami Habib
    • 1
    • 2
  • Cynthia L. Hooper
    • 2
    • 3
  1. 1.Department of PsychiatryUniversity of OttawaOttawaCanada
  2. 2.Psychopharmacology UnitRoyal Ottawa HospitalOttawaCanada
  3. 3.Institute of Mental Health Research, Royal Ottawa HospitalOttawaCanada

Personalised recommendations